FDA approves Bristol Myers Squibb’s Cobenfy
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Subscribe To Our Newsletter & Stay Updated